Abstract:Objective To evaluate the clinical effect and short-term safety of telbivudine administered in late pregnancy for blocking mother-to-child transmission of HBV in pregnant women with high HBV DNA load.Methods Pregnant women with positive HBsAg and HBeAg and HBV DNA ≥2 × 106 IU/ml who underwent blockade of mother-to-child transmission in The First Hospital of Jilin University from July 2012 to June 2015 were enrolled.These patients were informed of current methods for blocking mother-to-child transmission of hepatitis B,and according to their own will,they were divided into active/passive immunization + telbivudine (telbivudine group) and active/passive immunization group (immunization group).The patients in the telbivudine group were given oral telbivudine (600 mg,once a day) from week 32 of pregnancy to delivery,and those in the immunization group were not given antiviral therapy.The infants in both groups were given 20 μg hepatitis B vaccine combined with 100 IU hepatitis B immunoglobulin after birth.Positive HBsAg in infants at an age of 7 months was defined as failed blockade of mother-to-child transmission.The t-test was used for comparison of normally distributed continuous data between groups,and the Wilcoxon rank sun test was used for comparison of non-normally distributed continuous data between groups;the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups.Results A total of 447 pregnant women were enrolled,and there were 81 pregnant women in the telbivudine group and 366 women in the immunization group.Compared with the immunization group,the telbivudine group had a significantly higher mean age (28.8-± 3.3 years vs 27.6 ± 3.8 years,t =-2.55,P =0.01) and a significantly higher proportion of pregnant women with HBV DNA load ＞ 108 IU/ml (82.7％ vs 61.5％,x2 =13.21,P ＜0.001).There were no significant differences in alanine aminotransferase level,delivery mode,and feeding pattern between the two groups (all P ＞ 0.05).No infants in the telbivudine group had positive HBsAg at an age of 7 months,while among the 370 infants in the immunization group,21 had positive HBsAg;there was a significant difference in positive rate between the two groups (0 vs 5.7％,P =0.02).No women experienced eclampsia,premature rupture of membranes,or postpartum bleeding,and there were no significant differences between the two groups of infants in premature birth rate,body length,body weight,and Apgar score (all P ＞ 0.05).Conclusion In addition to active and passive immunization for neonates,antiviral therapy for pregnant women with a high viral load in late pregnancy can significantly improve the blocking rate of mother-to-child transmission of HBV and achieve no mother-to-child transmission of hepatitis B,and the neonates have good short-term safety.

The effects of telbivudine on T lymphocyte subsets in pregnancy with hepatitis B virus

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

The Effect of Maternal Use of Telbivudine on Neonatal CD4+CD25+ Regulatory T Cells for the Prevention of Mother-to-child Transmission of Hepatitis B Virus.

Efficacy and Safety of Telbivudine in Different Trimesters of Pregnancy with High Viremia for Interrupting Perinatal Transmission of Hepatitis B Virus

Effect of withdrawal time on postpartum liver function in pregnant women receiving tenofovir disoproxil fumarate therapy for blocking mother to child transmission of hepatitis B

Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Safety and Efficacy of Telbivudine for Chronic Hepatitis B During the Entire Pregnancy: Long‐term Follow‐up

[Telbivudine for Prevention of Perinatal Transmission in Pregnant Women Infected with Hepatitis B Virus in Immune-Tolerant Phase: a Study of Efficacy and Safety of Drug Withdrawal].

Changes in serum levels of Th1/Th2 cytokines in HBeAg-positive pregnant women with HBV infection after telbivu-dine treatment

Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine

Safety of Telbivudine Treatment for Chronic Hepatitis B for the Entire Pregnancy

To explore remedial strategy for gravidas with high HBV DNA load to prevent mother-to-infant transmission during late gestation

Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up

Efficacy and Safety of Telbivudine and Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Vertical Transmission: A Real‐life Practice

Telbivudine Therapy for Gravidas with Chronic Hepatitis B Infection and Patients at Risk of Renal Impairment

Efficacy and safety of telbivudine versus lamivudine in interrupting mother-to-child transmission of HBV:a meta-analysis

Clinical Effect and Short-Term Safety of Telbivudine in Blocking Mother-to-child Transmission of HBV

[Predictive Value of Telbivudine in Preventing Mother-to-infant Transmission of Hepatitis B Virus in Pregnant Women with High Viremia].

Efficacy and Safety of Telbivudine to Prevent Mother-to-child Transmission of Hepatitis B Virus in Middle- and Late-Stage Pregnancy with High Viral Loads

Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B